Company Overview and News

6
Building A Hedged Portfolio Around Realty Income

2018-10-16 seekingalpha
In August, I mentioned how a hedged portfolio built around an AT&T position last year generated strong performance while strictly limiting risk.
TSCO O WCG OPRF ORLY

 
The MnM Portfolio, September 2018 - Marking My 100th SA Article, And Revisiting The First

2018-10-16 seekingalpha
This month’s article marks the forty-third installment in my ongoing series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
UNM VIG O FSC OPRF OSLE OCSL FSCFL STAG FSCE

39
Can A Dividend Growth Portfolio Beat Index Funds?

2018-10-15 seekingalpha
I compare two index based funds to a DG portfolio I created for an article 2 years ago.
WFCNP LMT XOM OPRF WMT CL WFC GEC GE O CLGQY JNJ GNE MSFT

45
Is AT&T Stock the Perfect Buy Amid the Chaos?

2018-10-11 investorplace
During the last two hours of Wednesday’s trading session, investors saw what stocks look like in distress. Major indices tumbled and many individual stocks were obliterated, but AT&T (NYSE:T) held its own for most of the session. Sure, AT&T stock fell 1.95%, but that’s less than half of the decline in the Nasdaq Composite and it outperformed both the S&P 500 and Dow Jones Industrial Average. Shares are still up 1% over the last month.
VTR SQ F TWX O NFLX OPRF TWC AMZN T VZ DLR

 
REITs Vs. Real Estate Crowdfunding: What's The Better Way To Invest In Real Estate

2018-10-11 seekingalpha
Real estate crowdfunding has gained in importance, and many today consider it to be a superior alternative to REITs.
OPRF PSA.A PSAXZ O PSA PLD SPG WPC

36
John's August Dividend Increases And Income Tracker - Retirement Accounts

2018-10-09 seekingalpha
This is the sixth month I have officially tracked dividend income (in an article) for John's Traditional and Roth IRA Accounts. His dividend income totaled $1,166.72.
POR CAT HTA RF LTC OPRF WMT KMI OMI WELL CBRL KMR CVB ABBV BBT DUKH GD NYSE MAIN KMB CLDT WPC ABBV OXY BA PK SCG HRNNF TD VLY CONE BOE MSCA SCU TD VTR RDS.A H TNTTF O PACW DUK MSCA.CL SCHW PEP CVX KMRFZ

9
Sand In My Shoes - September Update

2018-10-08 seekingalpha
During the month of September the Soule household was quite busy and I fell out of my routine.
SOJA SO AMGN O OPRF CVS MMP AET

 
An A-Rated REIT That Looks Really Sweet

2018-10-08 seekingalpha
I consider flex space to be an attractive property sector and it’s relatively unknown to many REIT investors.
OPRF PSA.A PSAXZ O PSB PSA SPG

1
Demystifying The Mystery Behind STAG Industrial

2018-10-08 seekingalpha
Although the company is considered an industrial REIT, the company is unique in that it focuses on properties in secondary markets.
O GPT OPRF STAG

63
Sand In My Shoes - August (Yes, August) Update

2018-10-08 seekingalpha - 1
One new position was added during the month, no sales occurred except for the S&P 500 Index fund.
SOJA OPRF CVS BAC AAPL CSCO MMP CSCOI SO BAC C O HRL BLK CGBBW ITW

48
My Dividend Growth Portfolio - Q3 2018 Summary

2018-10-07 seekingalpha
I believe that someone who writes about financial assets should share his main holdings with his readers.
FB GIS RDS.B TXN TWX O GOOG OPRF TWC NKE KHC SBUX MSFT ADM OHI MCD

 
Realty Income Without A Margin Of Safety

2018-10-05 seekingalpha
Realty Income has returned more than 23% since its February low, which was approximately when Seeking Alpha contributor Robert Ruggirello, CFA, noted it was fairly valued.
O OPRF

7
Why Realty Income Corp. (O) is a Great Dividend Stock Right Now

2018-10-05 zacks
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
O WBA OPRF LMAT YY

9
Take Charge With These 5 'Fortress' REITs

2018-10-05 seekingalpha
Maintaining a healthy balance sheet is a tremendous driver for REIT performance, as it suggests discipline and the commitment by the management team to drive earnings growth.
BXP OPRF PSA.A SHLD EQR PSAXZ O PSB PSA SPG

63
Q3 Portfolio Review

2018-10-05 seekingalpha - 1
This is the third quarter review of my retirement income portfolio. It was a very active quarter that included a final pension rollover to my IRA. About half of the rollover funds have been deployed. Some existing positions were trimmed to take profit and to diversify. In recent weeks, I've written articles about the 19 new positions, so this review will be a brief summary.
TXN CNUTF XOM RDSB ENB OPRF RDSA FTS WMT BCE CSCO ABBV DUKH BAMGF SO UPS MAIN TYT KMB CMI ENB MFC RY 0945 BNS JNJ ITW RYDBF 7203 WPC SPG ABBV MSFT QCOM PFE CLX CDUAF BAMKF NNN SOJA TM ADP SKT EPD TD ETN BNS MSCA AAPL BIP RYDAF TD CSCOI BAM BEP CU VTR IBM RDS.B RY RDS.A TNTTF APLE O DUK FDX TOYOF MSCA.CL BLK HP PEP ADPVV FTS PPL MFC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...